Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 9, 2006, Pages 1931-1935

  Niwa, Toshiro ^a   Yamamoto, Sachiko ^a   Saito, Miho ^a   Kobayashi, Naoto ^a   Ikeda, Kaoru ^a   Noda, Yasuo ^a   Takagi, Akira ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Azasetron; Cytochrome P450; Human liver microsome; Ondansetron; Ramosetron; Serotonin 3 receptor antagonist

Indexed keywords

6 HYDROXYCHLORZOXAZONE; AZASETRON; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ETHOXYRESORUFIN DEETHYLASE; NIFEDIPINE; ONDANSETRON; RAMOSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; DRUG OXIDATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; MALE; METABOLIC INHIBITION; NORMAL HUMAN; PROTEIN BLOOD LEVEL; ULTRACENTRIFUGATION;

BENZIMIDAZOLES; BICYCLO COMPOUNDS, HETEROCYCLIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; ONDANSETRON; OXAZINES; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS;

EID: 33748337962     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1931     Document Type: Article

References (32)

1. Gonzalez F. J., Pharmacol. Ther., 45, 1-38 (1990).
2. Guengerich F. P., FASEB J., 6, 745-748 (1992).
3. Rendic S., Drug Metab. Rev., 34, 83-448 (2002).
4. Lin J. H., Lu A. Y. H., Clin. Pharmacokinet., 35, 361-390 (1998).
5. Huang S.-M., Lesko L. J., Williams R. L., J. Clin. Pharmacol., 39, 1006-1014 (1999).
6. Blower P. R., Cancer J., 8, 405-414 (2002).
7. Ozawa S., Rinsho Byori, 51, 168-173 (2003).
8. Niwa T., Shiraga T., Yamasaki S., Ishibashi K., Ohno Y., Kagayama A., Xenobiotica, 33, 717-729 (2003).
9. Niwa T., Inoue S., Shiraga T., Takagi A., Biol. Pharm. Bull., 28, 188-191 (2005).
10. Niwa T., Shiraga T., Hashimoto T., Kagayama A., Biol. Pharm. Bull., 27, 97-99 (2004).
11. Niwa T., Shiraga T., Hashimoto T., Kagayama A., Biol. Pharm. Bull., 27, 415-417 (2004).
12. Ikeda T., Nishimura K., Taniguchi T., Yoshimura T., Hata T., Kashiyama E., Kudo S., Miyamoto G., Kobayashi H., Kobayashi S., Okazaki O., Hakusui H., Aoyama E., Yoshimura Y., Yamada Y., Yoshikawa M., Otsuka M., Niwa T., Kagayama A., Suzuki S., Satoh T., Xenobio. Metab. Dispos., 16, 115-126 (2001).
13. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacobio-Dyn., 4, 879-885 (1981).
14. Akaike H., Trans. Automat. Control, 19, 716-723 (1974).
15. Obach R. S., Drug Metab. Dispos., 25, 1359-1369 (1997).
16. Izumi T., Hosiyama K., Enomoto S., Sasahara K., Sugiyama Y., J. Pharmacol. Exp. Ther., 280, 1392-1400 (1997).
17. Venkatakrishnan K., von Moltke L. L., Obach R. S., Greenblatt D. J., J. Pharmacol. Exp. Ther., 293, 343-350 (2000).
18. Austin R. P., Barton P., Cockroft S. L., Wenlock M. C., Riley R. J., Drug Metab. Dispos., 30, 1497-1503 (2002).
19. Igarashi S., Tanaka K., Yamamura H., Sawai K., Isobe M., Masui H., Kataoka S., Ishikawa M., Oka T., Kiso To Rinsho, 26, 2535-2547 (1992).
20. Hoshida E., Ono Y., Oshiba S., Kitamura A., Isobe M., Mori H., Kadobe Y., Shimomukai T., Wakiya M., Rinsho Iyaku, 12, 2483-2501 (1996).
21. Akasaka Y., Tanaka K., Fukuda T., Oizumi K., Kudo S., Isobe M., Niitani H., Rinsho Iyaku, 12, 3131-3147 (1996).
22. Ishikawa K., Morita Y., Kishi A., Kumai R., Kondo A., Ishitani K., Urushizaki I., Ishikawa M., Wada M., Kitamura S., Isobe M., Jpn. Pharmacol. Ther., 20, 2557-2569 (1992).
23. Dixon C. M., Colthup P. V., Serabjit-Singh C. J., Kerr B. M., Boehlert C. C., Park G. R., Tarbit M. H., Drug Metab. Dispos., 23, 1225-1230 (1995).
24. Ashforth E. I. L., Palmer J. L., Bye A., Bedding A., Br. J. Clin. Pharmacol., 37, 389-391 (1994).
25. Colthup P. V., Felgate C. C., Palmer J. L., Scully N. L., J. Pharm. Sci., 80, 868-871 (1991).
26. Kumagaya Y., Nakashima H., Kotegawa T., Shiga T., Ohira H., Oribe H., Koike Y., Ohashi K., Ebihara A., Murayama M., Rinsho Iyaku, 8, 1495-1504 (1992).
27. Nakajima M., Kanemaru M., Miura H., Takeshige T., Atsuta Y., Jpn. J. Clin. Exp. Med., 71, 2461-2468 (1994).
28. Nakajima M., Kanemaru M., Miura H., Takeshige T., Atsuta Y., Jpn. J. Clin. Exp. Med., 72, 2912-2926 (1995).
29. Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., Sugiyama Y., Pharmacol. Rev., 50, 387-411 (1998).
30. Ito K., Iwatsubo T., Kanamitsu S., Nakajima Y., Sugiyama Y., Ann. Rev. Pharmacol. Toxicol., 38, 461-499 (1998).
31. de Jonge M. E., Huitema A. D. R., van Dam S. M., Rodenhuis S., Beijnen J. H., Anti-Cancer Drugs, 16, 331-336 (2005).
32. Gilbert C. J., Petros W. P., Vredenburgh J., Hussein A., Ross M., Rubin P., Fehdrau R., Cavanaugh C., Berry D., McKinstry C., Peters W. P., Cancer Chemother. Pharmacol., 42, 497-503 (1998).